Your browser doesn't support javascript.
loading
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Shoushtari, Alexander N; Olszanski, Anthony J; Nyakas, Marta; Hornyak, Thomas J; Wolchok, Jedd D; Levitsky, Victor; Kuryk, Lukasz; Hansen, Thomas B; Jäderberg, Magnus.
Affiliation
  • Shoushtari AN; Department of Medicine (Melanoma Service), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Olszanski AJ; Weill Cornell Medicine, New York, New York.
  • Nyakas M; Department of Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Hornyak TJ; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Wolchok JD; Department of Dermatology and University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
  • Levitsky V; Department of Medicine (Melanoma Service), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kuryk L; Weill Cornell Medicine, New York, New York.
  • Hansen TB; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jäderberg M; Parker Institute for Cancer Immunotherapy, San Francisco, California.
Clin Cancer Res ; 29(1): 100-109, 2023 01 04.
Article in En | MEDLINE | ID: mdl-36112545
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Melanoma Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Melanoma Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: